Stock analysts at Mizuho assumed coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report issued on Monday, The Fly reports. The firm set a “neutral” rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the stock. Wedbush boosted their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an “outperform” rating in a report on Thursday, January 4th. HC Wainwright set a $37.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a report on Thursday, January 4th. BMO Capital Markets set a $44.00 target price on shares of Audentes Therapeutics and gave the company a “buy” rating in a report on Friday, January 5th. William Blair started coverage on shares of Audentes Therapeutics in a report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price for the company. Finally, ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Audentes Therapeutics has a consensus rating of “Buy” and an average target price of $35.00.
Audentes Therapeutics (BOLD) traded up $1.47 on Monday, hitting $32.80. 215,757 shares of the stock traded hands, compared to its average volume of 575,381. Audentes Therapeutics has a 1 year low of $13.90 and a 1 year high of $41.80. The stock has a market capitalization of $1,138.73, a PE ratio of -9.40 and a beta of 0.41.
A number of hedge funds have recently made changes to their positions in BOLD. SG Americas Securities LLC bought a new position in shares of Audentes Therapeutics in the third quarter worth approximately $143,000. Nationwide Fund Advisors boosted its position in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 6,384 shares during the period. Wells Fargo & Company MN boosted its position in shares of Audentes Therapeutics by 86.1% in the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock worth $404,000 after purchasing an additional 6,667 shares during the period. Teacher Retirement System of Texas bought a new position in shares of Audentes Therapeutics in the fourth quarter worth approximately $208,000. Finally, Ardsley Advisory Partners boosted its position in shares of Audentes Therapeutics by 59.7% in the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 7,500 shares during the period. 64.94% of the stock is owned by institutional investors and hedge funds.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.